LCL-iPSC4802
NCHi001-A
General
Cell Line |
|
hPSCreg name | NCHi001-A |
Cite as: | NCHi001-A (RRID:CVCL_C1NN) |
Alternative name(s) |
LCL-iPSC4802
|
Cell line type | Human induced pluripotent stem cell (hiPSC) |
Similar lines | No similar lines found. |
Last update | 7th November 2022 |
User feedback | |
Provider |
|
Generator | Nationwide Children's Hospital (NCH) |
External Databases |
|
BioSamples | SAMEA110474014 |
Cellosaurus | CVCL_C1NN |
Wikidata | Q114312466 |
General Information |
|
Publications | |
* Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: allowed
Commercial use: allowed
|
Donor Information
General Donor Information |
|
Sex | female |
Phenotype and Disease related information (Donor) |
|
Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
BioSamples | SAMEA111396657 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Please provide contact information of the holder of the original Donor Information Sheet. | kim.mcbride@nationwidechildrens.org |
Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
If you do not hold the Donor Consent Form, do you know who does? | Yes |
Please provide the contact information | kim.mcbride@nationwidechildrens.org |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | anonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
How may genetic information associated with the cell line be accessed? | Open Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | Yes |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | Genetics of CVD |
Approval number | Genetics of CVD IRB09-00339 |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Source cell line name |
EBV-immortalized lymphoblastoid cells Derived from same source line (potentially other lot and donor, see below):
|
Source cell type |
Human cell line from tissue infected with Epstein-Barr virus, resembling a lymphoblast.
Synonyms
|
Reprogramming method |
|
Vector type | Non-integrating |
Vector | Sendai virus |
Is reprogramming vector detectable? |
No |
Methods used |
PCR, RT-PCR
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
Unknown |
Derived under GMP? |
Unknown |
Available as clinical grade? |
Unknown |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
SOX2 |
Yes |
|||||
TRA 1-60 |
Yes |
Marker | Present | Absent |
mCpG | ||
OCT4 |
Self-renewal
Positive
Endoderm
Positive
Mesoderm
Positive
Ectoderm score
Positive
Data analysis report
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
In vitro directed differentiation
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.